Market Overview - The medical beauty sector experienced a decline of 0.93% on November 7, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1] Stock Performance - The closing prices and performance of key stocks in the medical beauty sector are as follows: - *ST Meigu: Closed at 4.02, up 1.77% with a trading volume of 143,600 shares and a turnover of 57.01 million yuan [1] - Jinbo Biological: Closed at 234.00, up 0.02% with a trading volume of 7,738.5 shares and a turnover of 1.83 billion yuan [1] - Huaxi Biological: Closed at 49.78, down 0.04% with a trading volume of 17,300 shares and a turnover of 86.15 million yuan [1] - Ai Meike: Closed at 149.16, down 1.87% with a trading volume of 30,900 shares and a turnover of 465 million yuan [1] Capital Flow - The medical beauty sector saw a net outflow of 46.6453 million yuan from main funds, while retail investors contributed a net inflow of 34.3979 million yuan [1] - The capital flow for key stocks is as follows: - *ST Meigu: Net outflow of 2.6832 million yuan, down 4.71% [2] - Huaxi Biological: Net outflow of 3.3342 million yuan, down 3.87% [2] - Ai Meike: Net outflow of 40.6279 million yuan, down 8.74% [2]

证券代码：000615 证券简称：*ST美谷 公告编号：2025-092 奥园美谷科技股份有限公司 关于对襄阳隆运减资的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、对外投资情况概述 奥园美谷科技股份有限公司（以下简称"公司"）分别于 2016 年 9 月 7 日 和 2016 年 9 月 26 日召开的第八届董事会第十六次会议和 2016 年第四次临时股 东大会，审议通过了《关于对外投资设立产业基金暨关联交易的议案》，公司与 京汉控股集团有限公司、北京隆运私募基金管理有限公司等共同发起设立襄阳隆 运股权投资合伙企业（有限合伙）（以下简称"襄阳隆运"），具体详见公司于 2016 年 9 月 9 日和 2016 年 9 月 27 日在巨潮资讯网（www.cninfo.com.cn，下同） 披露的《关于投资设立产业基金暨关联交易的公告》《第八届董事会第十六次会 议决议公告》和《2016 年第四次临时股东大会决议公告》；公司分别于 2018 年 9 月 5 日和 2018 年 9 月 21 日召开的第九届董事会第十二次会议和 2018 年第九次 临时股东 ...

Core Viewpoint - Aoyuan Meigu Technology Co., Ltd. (stock abbreviation: *ST Meigu, stock code: 000615) has announced a resolution from its 27th meeting of the 11th Board of Directors, focusing on capital structure optimization and financial cost reduction through a capital reduction of approximately 108 million yuan for Xiangyang Longyun Equity Investment Partnership [1][3]. Group 1: Board Meeting Overview - The board meeting was held on November 5, 2025, with all 9 directors present, and the meeting procedures complied with relevant laws and regulations [2]. - All resolutions were passed unanimously with 9 votes in favor, 0 against, and 0 abstentions [2]. Group 2: Capital Reduction Details - The board approved a capital reduction of approximately 10.791 million yuan for Xiangyang Longyun, which represents 78.05% of the company's most recent audited net assets [3]. - The capital reduction will be proportionally distributed among partners based on their shareholding ratios, and the consolidation scope of the company will remain unchanged post-reduction [3]. Group 3: Shareholder Meeting Proposal - The board proposed to convene the 2025 third extraordinary general meeting of shareholders on November 25, 2025, to discuss the capital reduction and amendments to the company’s articles of association [4]. - The meeting will address two main topics: the approved capital reduction and the proposed amendments to the articles of association and governance systems [4]. - Aoyuan Meigu stated that these measures are crucial for strategic adjustments, enhancing capital efficiency and overall operational effectiveness [4].

Core Viewpoint - *ST Meigu's strategic adjustment aims to optimize capital structure, reduce overall financial costs, and enhance operational efficiency through a capital reduction of approximately 107.91 million yuan [1] Group 1 - The company plans to reduce capital for Xiangyang Longyun by about 107.91 million yuan, which accounts for approximately 78.05% of the latest audited net assets [1] - All partners will proportionally reduce their capital according to their shareholding ratios [1] - The completion of this capital reduction will not change the scope of the company's consolidated financial statements [1]

证券代码：000615 证券简称：*ST美谷 公告编号：2025-091 奥园美谷科技股份有限公司 关于召开 2025 年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、召开会议基本情况 1、股东会届次：2025 年第三次临时股东会。 2、股东会召集人：公司董事会。 3、会议召开的合法、合规性：本次股东会的召集程序符合有关法律、行政 法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开日期： （1）现场会议时间：2025 年 11 月 25 日（星期二）下午 15:30 开始； （2）网络投票时间：2025 年 11 月 25 日 通过深圳证券交易所交易系统进行网络投票的时间为：2025 年 11 月 25 日的 交易时间，即上午 9:15-9:25，9:30-11:30，下午 13:00-15:00； 通过深圳证券交易所互联网投票系统进行网络投票的时间为：2025 年 11 月 25 日上午 9:15 至下午 15:00 间的任意时间。 5、会议召开的方式： 本次股东会采用现场表决与网络投票相结合的方式召开： （1）于股 ...

本议案尚需提交公司股东会审议。 具体内容详见刊登在《证券时报》和巨潮资讯网（www.cninfo.com.cn）的 《关于对襄阳隆运减资的公告》。 表决结果：9 票同意，0 票反对，0 票弃权。 证券代码：000615 证券简称：*ST美谷 公告编号：2025-090 奥园美谷科技股份有限公司 第十一届董事会第二十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 奥园美谷科技股份有限公司（以下简称"公司"）第十一届董事会第二十七 次会议通知于 2025 年 11 月 3 日以电子通讯方式通知公司全体董事，会议于 2025 年 11 月 5 日下午以现场结合电子通讯方式召开。本次会议由董事长刘涛先生主 持，会议应到董事 9 人，实到董事 9 人。公司部分监事、高级管理人员列席了会 议。会议的召集、召开程序符合《中华人民共和国公司法》《公司章程》和《公 司董事会议事规则》的有关规定。经与会董事认真审议，通过了如下决议： 一、审议通过了《关于对襄阳隆运减资的议案》 基于公司发展战略调整，为优化公司资本结构，降低整体财务成本并提升经 营效益，董事会同意 ...

Group 1 - The core point of the article is that *ST Meigu (SZ 000615) held its 27th meeting of the 11th Board of Directors on November 5, 2025, to discuss the proposal for the third extraordinary shareholders' meeting in 2025 [1] - For the first half of 2025, *ST Meigu's revenue composition is as follows: medical beauty services accounted for 57.47%, bio-based fibers accounted for 38.54%, and others accounted for 3.99% [1] - As of the report date, *ST Meigu has a market capitalization of 3 billion yuan [1]

Group 1 - The medical beauty sector increased by 0.18% on November 6, with *ST Meigu leading the gains [1] - The Shanghai Composite Index closed at 4007.76, up 0.97%, while the Shenzhen Component Index closed at 13452.42, up 1.73% [1] - The trading volume and turnover for *ST Meigu were 137,900 hands and 53.13 million yuan, respectively, with a price increase of 3.95% [1] Group 2 - The medical beauty sector experienced a net outflow of 34.96 million yuan from main funds, while retail investors saw a net inflow of 36.62 million yuan [1] - Individual stock performances included *ST Meigu with a 3.95% increase, Aimeike with a 0.38% increase, Huaxi Biological with a 0.52% decrease, and Jinbo Biological with a 2.54% decrease [1] - The net fund flow for *ST Meigu was -3.52 million yuan, indicating a decrease of 6.63% [2]

Group 1 - The medical beauty sector experienced a decline of 2.68% on November 4, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] - Major stocks in the medical beauty sector showed varied performance, with *ST Meigu closing at 3.74 (+0.27%), Huaxi Biological at 52.05 (-2.01%), Aimeike at 151.92 (-3.46%), and Jinbo Biological at 243.02 (-4.84%) [1] Group 2 - The medical beauty sector saw a net outflow of 101 million yuan from institutional investors, while retail investors had a net inflow of 79.55 million yuan [1] - The trading volume and turnover for key stocks included *ST Meigu with 140,600 shares traded and a turnover of 53.3 million yuan, Huaxi Biological with 29,200 shares and 153 million yuan, Aimeike with 43,500 shares and 669 million yuan, and Jinbo Biological with 15,400 shares and 378 million yuan [1]

Market Overview - The medical beauty sector experienced a decline of 1.4% on November 3, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Individual Stock Performance - *ST Meigu (000615) closed at 3.73, with an increase of 4.19% and a trading volume of 150,000 shares, totaling a transaction value of 5.5589 million yuan [1] - Jinbo Biological (920982) closed at 255.37, up 1.63%, with a trading volume of 15,700 shares and a transaction value of 403 million yuan [1] - Huaxi Biological (688363) closed at 53.12, down 1.61%, with a trading volume of 29,400 shares and a transaction value of 156 million yuan [1] - Ai Meike (300896) closed at 157.37, down 1.70%, with a trading volume of 33,400 shares and a transaction value of 5.271 billion yuan [1] Capital Flow Analysis - The medical beauty sector saw a net inflow of 2.7789 million yuan from main funds, while retail investors experienced a net outflow of 3.33256 million yuan [1] - Main funds for *ST Meigu showed a net inflow of 6.9892 million yuan, while retail investors had a net outflow of 652.99 thousand yuan [2] - Ai Meike had a net inflow of 1.4812 million yuan from main funds, but a net outflow of 1.89798 million yuan from retail investors [2] - Huaxi Biological experienced a net outflow of 5.6915 million yuan from main funds and a net outflow of 781.58 thousand yuan from retail investors [2]